Chris A. Rallis's most recent trade in Fennec Pharmaceuticals Inc was a trade of 2,127 Common Shares done . Disclosure was reported to the exchange on July 7, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2025 | 2,127 | 178,406 | - | - | Common Shares | |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.35 per share. | 07 Jul 2025 | 2,127 | 55,911 (0%) | 0% | 2.3 | 4,998 | Common Shares |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Sale of securities on an exchange or to another person at price $ 8.71 per share. | 07 Jul 2025 | 1,119 | 54,792 (0%) | 0% | 8.7 | 9,746 | Common Shares |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 20,000 | 200,533 | - | - | Stock Option | |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Apr 2025 | 2,173 | 180,533 | - | - | Common Shares | |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.30 per share. | 11 Apr 2025 | 2,173 | 55,193 (0%) | 0% | 2.3 | 4,998 | Common Shares |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Sale of securities on an exchange or to another person at price $ 4.95 per share. | 11 Apr 2025 | 1,409 | 53,784 (0%) | 0% | 5.0 | 6,975 | Common Shares |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.51 per share. | 14 Feb 2025 | 1,992 | 54,206 (0%) | 0% | 2.5 | 5,000 | Common Shares |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 1,992 | 182,706 | - | - | Common Shares | |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Sale of securities on an exchange or to another person at price $ 6.82 per share. | 14 Feb 2025 | 1,186 | 53,020 (0%) | 0% | 6.8 | 8,089 | Common Shares |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 10,000 | 184,698 | - | - | Common Shares | |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.69 per share. | 02 Dec 2024 | 10,000 | 58,623 (0%) | 0% | 2.7 | 26,900 | Common Shares |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Sale of securities on an exchange or to another person at price $ 6.14 per share. | 02 Dec 2024 | 6,409 | 52,214 (0%) | 0% | 6.1 | 39,351 | Common Shares |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2024 | 1,960 | 194,698 | - | - | Common Shares | |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.55 per share. | 08 Oct 2024 | 1,960 | 50,029 (0%) | 0% | 2.6 | 4,998 | Common Shares |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Sale of securities on an exchange or to another person at price $ 4.53 per share. | 08 Oct 2024 | 1,406 | 48,623 (0%) | 0% | 4.5 | 6,369 | Common Shares |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 20,000 | 196,658 | - | - | Stock Option | |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.79 per share. | 05 Jul 2024 | 1,792 | 47,630 (0%) | 0% | 2.8 | 5,000 | Common Shares |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jul 2024 | 1,792 | 179,802 | - | - | Common Shares | |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Sale of securities on an exchange or to another person at price $ 6.03 per share. | 05 Jul 2024 | 1,173 | 46,457 (0%) | 0% | 6.0 | 7,073 | Common Shares |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2024 | 1,389 | 181,594 | - | - | Common Shares | |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.45 per share. | 15 Apr 2024 | 1,389 | 45,838 (0%) | 0% | 10.4 | 14,515 | Common Shares |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Sale of securities on an exchange or to another person at price $ 10.45 per share. | 15 Apr 2024 | 800 | 44,449 (0%) | 0% | 10.5 | 8,360 | Common Shares |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.31 per share. | 26 Mar 2024 | 4,329 | 45,249 (0%) | 0% | 2.3 | 10,000 | Common Shares |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2024 | 4,329 | 182,983 | - | - | Common Shares | |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Sale of securities on an exchange or to another person at price $ 10.97 per share. | 26 Mar 2024 | 2,114 | 40,920 (0%) | 0% | 11.0 | 23,191 | Common Shares |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Dec 2023 | 3,144 | 184,168 | - | - | Common Shares | |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.59 per share. | 26 Dec 2023 | 3,144 | 46,178 (0%) | 0% | 1.6 | 4,999 | Common Shares |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Sale of securities on an exchange or to another person at price $ 10.90 per share. | 26 Dec 2023 | 1,390 | 44,788 (0%) | 0% | 10.9 | 15,151 | Common Shares |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Sale of securities on an exchange or to another person at price $ 8.25 per share. | 20 Nov 2023 | 269 | 43,034 (0%) | 0% | 8.2 | 2,219 | Common Shares |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Sale of securities on an exchange or to another person at price $ 7.85 per share. | 18 Aug 2023 | 673 | 43,303 (0%) | 0% | 7.8 | 5,283 | Common Shares |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.72 per share. | 24 Jul 2023 | 16,666 | 50,772 (0%) | 0% | 0.7 | 12,000 | Common Shares |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jul 2023 | 16,666 | 187,312 | - | - | Common Shares | |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Sale of securities on an exchange or to another person at price $ 8.17 per share. | 24 Jul 2023 | 6,796 | 43,976 (0%) | 0% | 8.2 | 55,523 | Common Shares |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.96 per share. | 06 Jul 2023 | 5,280 | 34,106 (0%) | 0% | 1.0 | 5,069 | Common Shares |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jul 2023 | 5,208 | 203,978 | - | - | Common Shares | |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Sale of securities on an exchange or to another person at price $ 8.47 per share. | 06 Jul 2023 | 2,207 | 28,826 (0%) | 0% | 8.5 | 18,693 | Common Shares |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2023 | 20,000 | 209,186 | - | - | Stock Option | |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Sale of securities on an exchange or to another person at price $ 7.36 per share. | 19 May 2023 | 925 | 31,033 (0%) | 0% | 7.4 | 6,808 | Common Shares |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Sale of securities on an exchange or to another person at price $ 7.36 per share. | 19 May 2023 | 833 | 31,958 (0%) | 0% | 7.4 | 6,131 | Common Shares |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.94 per share. | 17 Apr 2023 | 1,700 | 33,777 (0%) | 0% | 2.9 | 4,998 | Common Shares |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.34 per share. | 17 Apr 2023 | 986 | 32,791 (0%) | 0% | 8.3 | 8,223 | Common Shares |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.40 per share. | 03 Mar 2023 | 4,166 | 34,184 (0%) | 0% | 2.4 | 9,998 | Common Shares |
| Fennec Pharmaceuticals Inc | Chris A. Rallis | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.09 per share. | 03 Mar 2023 | 2,177 | 32,077 (0%) | 0% | 9.1 | 19,789 | Common Shares |